Impact drugs targeting cardiometabolic risk on the gut microbiota.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
18
12
2020
medline:
15
12
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
Alterations in the gut microbiome composition or function are associated with risk factors for cardiometabolic diseases, including hypertension, hyperlipidemia and hyperglycemia. Based on recent evidence that also oral medications used to treat these conditions could alter the gut microbiome composition and function and, vice versa, that the gut microbiome could affect the efficacy of these treatments, we reviewed the literature on these observed interactions. While the interaction of metformin with the gut microbiome has been studied most, other drugs that target cardiometabolic risk are gaining attention and often showed associations with alterations in microbiome-related features, including alterations in specific microbial taxa or pathways, microbiome composition or microbiome-derived metabolites, while the gut microbiome was also involved in drug metabolism and drug efficacy. As for metformin, for some of them even a potential therapeutic effect via the gut microbiome is postulated. However, exact mechanisms remain to be elucidated. There is growing interest in clarifying the interactions between the gut microbiome and drugs to treat hypertension, hyperlipidemia and hyperglycemia as well as the first pass effect of microbiome on drug efficacy. While mostly analysed in animal models, also human studies are gaining more and more traction. Improving the understanding of the gut microbiome drug interaction can provide clinical directions for therapy by optimizing drug efficacy or providing new targets for drug development.
Identifiants
pubmed: 33332920
doi: 10.1097/MOL.0000000000000727
pii: 00041433-202102000-00006
doi:
Substances chimiques
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-54Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016; 375:2369–2379.
Kappel BA, Federici M. Gut microbiome and cardiometabolic risk cardiometabolic diseases gut microbiota. Rev Endocr Metab Disord 2019; 20:399–406.
Warmbrunn MV, Herrema H, Aron-Wisnewsky J, et al. Gut microbiota: a promising target against cardiometabolic diseases. Expert Rev Endocrinol Metab 2020; 15:13–27.
Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science 2016; 352:560–564.
Deschasaux M, Bouter KE, Prodan A, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med 2018; 24:1526–1531.
Jackson MA, Verdi S, Maxan ME, et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun 2018; 9:1–8.
Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut 2020; 69:1510–1519.
Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of nonantibiotic drugs on human gut bacteria. Nature 2018; 555:623–628.
Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 2019; 570:462–467.
Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun 2020; 11:1–11.
Robles-Vera I, Toral M, de la Visitación N, et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. Br J Pharmacol 2020; 177:2006–2023.
Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut microbiota in hypertension and atherosclerosis: a review. Nutrients 2020; 12:1–22.
Verhaar BJH, Collard D, Prodan A, et al. Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study. Eur Heart J 2020; ehaa704[Epub ahead of print].
Wu D, Tang X, Ding L, et al. Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. Biomed Pharmacother 2019; 116:109040.
Choi MS, Yu JS, Yoo HH, Kim DH. The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. Pharmacol Res 2018; 130:164–171.
Yoo HH, Kim IS, Yoo DH, Kim DH. Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. J Hypertens 2016; 34:156–162.
Zhang J, Chen Y, Sun Y, et al. Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine. Drug Deliv 2018; 25:1175–1181.
Konop M, Radkowski M, Grochowska M, et al. Enalapril decreases rat plasma concentration of TMAO, gut bacteria-derived cardiovascular marker. Biomarkers 2018; 23:380–385.
Jaworska K, Huc T, Samborowska E, et al. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS One 2017; 12:1–16.
Yang T, Aquino V, Lobaton GO, et al. Sustained captopril-induced reduction in blood pressure is associated with alterations in gut–brain axis in the spontaneously hypertensive rat. J Am Heart Assoc 2019; 8:e010721.
Li HB, Yang T, Richards EM, et al. Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring. Hypertension 2020; 75:1315–1324.
Chan YK, Brar MS, Kirjavainen PV, et al. High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus . BMC Microbiol 2016; 16:1–13.
Brocker CN, Velenosi T, Flaten HK, et al. Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites. Hum Genomics 2020; 14:1–9.
Jie Z, Xia H, Zhong SL, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017; 8:1–11.
Song SC, An YM, Shin JH, et al. Beneficial effects of a probiotic blend on gastrointestinal side effects induced by leflunomide and amlodipine in a rat model. Benef Microbes 2017; 8:801–808.
Villette R, Pukar KC, Beliard S, et al. Unraveling host–gut microbiota dialogue and its impact on cholesterol levels. Front Pharmacol 2020; 11:1–15.
Kurilshikov A, Van Den Munckhof ICL, Chen L, et al. Gut microbial associations to plasma metabolites linked to cardiovascular phenotypes and risk: a cross-sectional study. Circ Res 2019; 124:1808–1820.
Catry E, Pachikian BD, Salazar N, et al. Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism. Life Sci 2015; 132:77–84.
Dias AM, Cordeiro G, Estevinho MM, et al. Gut bacterial microbiome composition and statin intake – a systematic review. Pharmacol Res Perspect 2020; 8:1–14.
Khan TJ, Ahmed YM, Zamzami MA, et al. Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats. Sci Rep 2018; 8:1–9.
Ryan PM, London LEE, Bjorndahl TC, et al. Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E −/− mice. Microbiome 2017; 5:1–13.
Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 2020; gutjnl-2019-319664[Epub ahead of print].
Sudun, Liu S, Xiao C, et al. Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin. Food Funct 2019; 10:6098–6109.
Kim J, Lee H, An J, et al. Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia. Front Microbiol 2019; 10:1–10.
Zimmermann F, Roessler J, Schmidt D, et al. Impact of the gut microbiota on atorvastatin mediated effects on blood lipids. J Clin Med 2020; 9:1596.
Zhang Q, Fan X, Ye R, et al. The effect of simvastatin on gut microbiota and lipid metabolism in hyperlipidemic rats induced by a high-fat diet. Front Pharmacol 2020; 11:522.
Zhao C, Hu Y, Chen H, et al. An in vitro evaluation of the effects of different statins on the structure and function of human gut bacterial community. PLoS One 2020; 15:1–17.
Vieira-Silva S, Falony G, Belda E, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 2020; 581:310–315.
Kummen M, Solberg OG, Storm-Larsen C, et al. Rosuvastatin alters the genetic composition of the human gut microbiome. Sci Rep 2020; 10:1–9.
Fangmann D, Theismann EM, Turk K, et al. Targeted microbiome intervention by microencapsulated delayed-release niacin beneficially affects insulin sensitivity in humans. Diabetes Care 2018; 41:398–405.
Tsuji Y, Kaji K, Kitade M, et al. Bile acid sequestrant, sevelamer ameliorates hepatic fibrosis with reduced overload of endogenous lipopolysaccharide in experimental nonalcoholic steatohepatitis. Microorganisms 2020; 8:925.
Brønden A, Mikkelsen K, Sonne DP, et al. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. Diabetes Obes Metab 2018; 20:1623–1631.
Fuchs CD, Paumgartner G, Mlitz V, et al. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2−/−mice by modulating composition, signalling and excretion of faecal bile acids. Gut 2018; 67:1683–1691.
Kusumoto Y, Irie J, Iwabu K, et al. Bile acid binding resin prevents fat accumulation through intestinal microbiota in high-fat diet-induced obesity in mice. Metabolism 2017; 71:1–6.
Kyriachenko Y, Falalyeyeva T, Korotkyi O, et al. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes 2019; 10:154–168.
Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol 2019; 15:569–589.
Pryor R, Martinez-Martinez D, Quintaneiro L, Cabreiro F. The role of the microbiome in drug response. Annu Rev Pharmacol Toxicol 2020; 60:417–435.
Rodriguez J, Hiel S, Delzenne NM. Metformin: old friend, new ways of action-implication of the gut microbiome? Curr Opin Clin Nutr Metab Care 2018; 21:294–301.
Whang A, Nagpal R, Yadav H. Bi-directional drug–microbiome interactions of antidiabetics. EBioMedicine 2019; 39:591–602.
Bailey CJ. Metformin: historical overview. Diabetologia 2017; 60:1566–1576.
Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 2017; 23:850–858.
Koh A, Mannerås-Holm L, Yunn NO, et al. Microbial imidazole propionate affects responses to metformin through p38γ-dependent inhibitory AMPK phosphorylation. Cell Metab 2020; 32:643–653.e4.
Pryor R, Norvaisas P, Marinos G, et al. Host–microbe–drug–nutrient screen identifies bacterial effectors of metformin therapy. Cell 2019; 178:1299–1312.e29.
Bryrup T, Thomsen CW, Kern T, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a nonblinded, one-armed intervention study. Diabetologia 2019; 62:1024–1035.
Elbere I, Kalnina I, Silamikelis I, et al. Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLoS One 2018; 13:1–17.
Nakajima H, Takewaki F, Hashimoto Y, et al. The effects of metformin on the gut microbiota of patients with type 2 diabetes: A two-center, quasi-experimental study. Life 2020; 10:1–15.
Ejtahed HS, Tito RY, Siadat SD, et al. Metformin induces weight loss associated with gut microbiota alteration in nondiabetic obese women: a randomized double-blind clinical trial. Eur J Endocrinol 2019; 180:165–176.
Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 2018; 24:1919–1929.
De La Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 2017; 40:54–62.
Chávez-Carbajal A, Pizano-Zárate ML, Hernández-Quiroz F, et al. Characterization of the gut microbiota of individuals at different T2D stages reveals a complex relationship with the host. Microorganisms 2020; 8:94.
Gaike AH, Paul D, Bhute S, et al. The gut microbial diversity of newly diagnosed diabetics but not of prediabetics is significantly different from that of healthy nondiabetics. mSystems 2020; 5:1–17.
Mishima E, Fukuda S, Kanemitsu Y, et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am J Physiol Ren Physiol 2018; 315:F824–F833.
Gu Y, Wang X, Li J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun 2017; 8:1785.
Qiu Y, Shen L, Fu L, et al. The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice. Diabetologia 2020; 63:1002–1016.
Zhang X, Fang Z, Zhang C, et al. Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial. Diabetes Ther 2017; 8:293–307.
Smits MM, Tonneijck L, Muskiet MHA, et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab 2016; 18:1217–1225.
van Bommel EJM, Herrema H, Davids M, et al. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: results of a double-blind randomized trial in patients with type 2 diabetes. Diabetes Metab 2020; 46:164–168.
Zhang F, Wang M, Yang J, et al. Response of gut microbiota in type 2 diabetes to hypoglycemic agents. Endocrine 2019; 66:485–493.
Wang Z, Saha S, Van Horn S, et al. Gut microbiome differences between metformin- and liraglutide-treated T2DM patients. Endocrinol Diabetes Metab 2018; 1:e00009.
Nguyen TLA, Vieira-silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech 2015; 8:1–16.
Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota–farnesoid x receptor axis modulates metabolic disease. Gastroenterology 2016; 151:845–859.
De Filippis F, Pasolli E, Tett A, et al. Distinct genetic and functional traits of human intestinal prevotella copri strains are associated with different habitual diets. Cell Host Microbe 2019; 25:444–453.e3.
Li L, Abou-Samra E, Ning Z, et al. An in vitro model maintaining taxon-specific functional activities of the gut microbiome. Nat Commun 2019; 10:4146.
Li L, Ning Z, Zhang X, et al. RapidAIM: a culture- and metaproteomics-based rapid assay of individual microbiome responses to drugs. Microbiome 2020; 8:1–16.
Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science 2019; 363:eaat9931.
Diener C, Gibbons SM, Resendis-Antonio O. MICOM: metagenome-scale modeling to infer metabolic interactions in the gut microbiota. mSystems 2020; 5:1–17.